With its renal denervation procedure, Medtronic plc (MDT) reported sustained long-term reductions in blood pressure.
Compared to a controlled reference group, patients who underwent radiofrequency renal denervation with the first generation Symplicity renal denervation system showed statistically significant improvements in office and ambulatory blood pressure.
According to the company, the data contributes to a growing body of evidence supporting the durability of the Symplicity blood pressure procedure.
At the 34th Transcatheter Cardiovascular Therapeutics (TCT) conference, the annual scientific symposium of the Cardiovascular Research Foundation, the data were presented as Late-Breaking Clinical Science and published simultaneously in The Lancet.
More than 60 countries around the world have approved the Symplicity Spyral renal denervation system for commercial use. In the United States, Canada, and Japan, however, it is limited to investigational use only.
